$GTHP
GUIDED THERAPEUTICS INC Stock $gthp

$gthp Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000147793224004869 Filed on August 14, 2024

Income Statement

Concept	2024 Q3	2024 Q2	2023 Q2
Revenue	$0.00	$0.00	$44.00K
YoY Change		-100.0%	780.0%
Cost Of Revenue	$0.00	$0.00	$33.00K
YoY Change	-100.0%	-100.0%	3200.0%
Gross Profit	$0.00	$0.00	$11.00K
YoY Change	-100.0%	-100.0%	175.0%
Gross Profit Margin			25.0%
Selling, General & Admin	$450.0K	$433.0K	$1.450M
YoY Change	-18.18%	-70.14%	103.65%
% of Gross Profit			13181.82%
Research & Development	$111.0K	$222.0K	$66.00K
YoY Change	60.87%	236.36%	633.33%
% of Gross Profit			600.0%
Depreciation & Amortization		$3.000K	$3.000K
YoY Change		0.0%
% of Gross Profit			27.27%
Operating Expenses	$561.0K	$655.0K	$1.516M
YoY Change	-9.37%	-56.79%	110.26%
Operating Profit	-$561.0K	-$655.0K	-$1.505M
YoY Change	-9.95%	-56.48%	109.9%
Interest Expense	$108.0K	$75.00K	$69.00K
YoY Change	52.11%	8.7%	-73.05%
% of Operating Profit
Other Income/Expense, Net	-$93.00K	-$54.00K	-$52.00K
YoY Change	72.22%	3.85%	-75.12%
Pretax Income	-$654.0K	-$709.0K	-$1.557M
YoY Change	-3.4%	-54.46%	68.14%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$654.0K	-$709.0K	-$1.557M
YoY Change	-3.4%	-54.46%	68.14%
Net Earnings / Revenue			-3538.64%
Basic Earnings Per Share	-$0.01	-$0.01	-$0.03
Diluted Earnings Per Share	-$0.01	-$0.01	-$0.03
COMMON SHARES
Basic Shares Outstanding	56.55M shares	55.69M shares	51.01M shares
Diluted Shares Outstanding	57.04M shares	55.99M shares	50.97M shares

Balance Sheet

Concept	2024 Q3	2024 Q2	2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments		$275.0K	$1.358M
YoY Change		-79.75%	204.48%
Cash & Equivalents	$194.0K	$275.0K	$1.358M
Short-Term Investments
Other Short-Term Assets	$211.0K	$112.0K	$91.00K
YoY Change	9.9%	23.08%	54.24%
Inventory	$636.0K	$632.0K	$573.0K
Prepaid Expenses
Receivables	$2.000K	$2.000K	$7.000K
Other Receivables		$0.00	$0.00
Total Short-Term Assets	$1.043M	$1.021M	$2.029M
YoY Change	-33.9%	-49.68%	83.95%
LONG-TERM ASSETS
Property, Plant & Equipment	$25.00K	$28.00K	$36.00K
YoY Change	-28.57%	-22.22%	-20.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$17.00K	$17.00K	$17.00K
YoY Change	0.0%	0.0%	0.0%
Total Long-Term Assets	$206.0K	$230.0K	$319.0K
YoY Change	-31.1%	-27.9%	-20.25%
TOTAL ASSETS
Total Short-Term Assets	$1.043M	$1.021M	$2.029M
Total Long-Term Assets	$206.0K	$230.0K	$319.0K
Total Assets	$1.249M	$1.251M	$2.348M
YoY Change	-33.46%	-46.72%	56.22%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.100M	$2.143M	$2.128M
YoY Change	-2.46%	0.7%	-11.48%
Accrued Expenses	$923.0K	$840.0K	$971.0K
YoY Change	14.37%	-13.49%	-19.49%
Deferred Revenue
YoY Change
Short-Term Debt		$1.336M	$1.240M
YoY Change		7.74%	228.04%
Long-Term Debt Due		$520.0K	$0.00
YoY Change			-100.0%
Total Short-Term Liabilities	$6.025M	$5.732M	$4.936M
YoY Change	24.64%	16.13%	-17.68%
LONG-TERM LIABILITIES
Long-Term Debt		$82.00K	$525.0K
YoY Change		-84.38%	-46.75%
Other Long-Term Liabilities		$104.0K	$202.0K
YoY Change		-48.51%	-29.62%
Total Long-Term Liabilities	$142.0K	$186.0K	$727.0K
YoY Change	-79.51%	-74.42%	-42.89%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.025M	$5.732M	$4.936M
Total Long-Term Liabilities	$142.0K	$186.0K	$727.0K
Total Liabilities	$6.167M	$5.918M	$5.663M
YoY Change	11.58%	4.5%	-22.09%
SHAREHOLDERS EQUITY
Retained Earnings	-$153.0M	-$152.3M	-$149.9M
YoY Change	1.57%	1.59%	3.8%
Common Stock	$3.446M	$3.442M	$3.438M
YoY Change	0.2%	0.12%	0.64%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$132.0K	$132.0K	$132.0K
YoY Change	0.0%	0.0%	0.0%
Treasury Stock Shares
Shareholders Equity	-$4.918M	-$4.667M	-$3.315M
YoY Change
Total Liabilities & Shareholders Equity	$1.249M	$1.251M	$2.348M
YoY Change	-33.46%	-46.72%	56.22%

Cashflow Statement

Concept	2024 Q3	2024 Q2	2023 Q2
OPERATING ACTIVITIES
Net Income	-$654.0K	-$709.0K	-$1.557M
YoY Change	-3.4%	-54.46%	68.14%
Depreciation, Depletion And Amortization		$3.000K	$3.000K
YoY Change		0.0%
Cash From Operating Activities		-$214.0K	-$438.0K
YoY Change		-51.14%	25.5%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities			$0.00
YoY Change
Cash From Investing Activities			$0.00
YoY Change			-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		44.00K	-41.00K
YoY Change		-207.32%	-147.13%
NET CHANGE
Cash From Operating Activities		-214.0K	-438.0K
Cash From Investing Activities			0.000
Cash From Financing Activities		44.00K	-41.00K
Net Change In Cash		-170.0K	-479.0K
YoY Change		-64.51%	71.68%
FREE CASH FLOW
Cash From Operating Activities		-$214.0K	-$438.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	818000	usd
CY2024Q2	us-gaap	Inventory Net InventoryNet	632000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	591000	usd
CY2024Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	7000	usd
CY2024Q2	us-gaap	Other Assets Current OtherAssetsCurrent	112000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	163000	usd
CY2024Q2	us-gaap	Assets Current AssetsCurrent	1021000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	1393000	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	28000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	32000	usd
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	185000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	227000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	17000	usd
CY2024Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	17000	usd
CY2024Q2	us-gaap	Assets Noncurrent AssetsNoncurrent	230000	usd
CY2023Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	276000	usd
CY2024Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	2143000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1991000	usd
CY2024Q2	gthp	Account Payable Related Parties Current AccountPayableRelatedPartiesCurrent	34000	usd
CY2023Q4	gthp	Account Payable Related Parties Current AccountPayableRelatedPartiesCurrent	32000	usd
CY2024Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	840000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1068000	usd
CY2024Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	748000	usd
CY2023Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	424000	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	99000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	91000	usd
CY2024Q2	gthp	Current Portion Of Long Term Debt Related Parties CurrentPortionOfLongTermDebtRelatedParties	520000	usd
CY2023Q4	gthp	Current Portion Of Long Term Debt Related Parties CurrentPortionOfLongTermDebtRelatedParties	39000	usd
CY2024Q2	us-gaap	Short Term Non Bank Loans And Notes Payable ShortTermNonBankLoansAndNotesPayable	112000	usd
CY2023Q4	us-gaap	Short Term Non Bank Loans And Notes Payable ShortTermNonBankLoansAndNotesPayable	59000	usd
CY2024Q2	gthp	Short Term Convertible Notes Payable Including Nonconvertible Penalty ShortTermConvertibleNotesPayableIncludingNonconvertiblePenalty	94000	usd
CY2023Q4	gthp	Short Term Convertible Notes Payable Including Nonconvertible Penalty ShortTermConvertibleNotesPayableIncludingNonconvertiblePenalty	1105000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4809000	usd
CY2024Q2	gthp	Current Portion Of Long Term Debt Related Parties Non Current CurrentPortionOfLongTermDebtRelatedPartiesNonCurrent	23000	usd
CY2023Q4	gthp	Current Portion Of Long Term Debt Related Parties Non Current CurrentPortionOfLongTermDebtRelatedPartiesNonCurrent	511000	usd
CY2024Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	186000	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	666000	usd
CY2024Q2	us-gaap	Liabilities Liabilities	5918000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	5475000	usd
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	56267000	shares
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	3442000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	3441000	usd
CY2024Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	141320000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	140983000	usd
CY2023Q4	us-gaap	Treasury Stock Value TreasuryStockValue	132000	usd
CY2024Q2	us-gaap	Treasury Stock Value TreasuryStockValue	132000	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-152317000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-151118000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-4667000	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1251000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1669000	usd
CY2024Q2	gthp	Preconfirmations Stockholders Equity PreconfirmationsStockholdersEquity	-4700000	usd
CY2023	us-gaap	Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants	400000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	28584580	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.50
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	1000000	shares
	gthp	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price Warrant Issued ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceWarrantIssued	0.30
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations	761500	shares
	gthp	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price Expired ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceExpired	0.37
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	28823080	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.50
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	35586980	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.46
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	5873750	shares
	gthp	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price Warrant Issued ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceWarrantIssued	0.25
	gthp	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Warrants Exchanged ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExchanged	1025000	usd
	gthp	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price Expired ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceExpired	0.25
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations	9478200	shares
	gthp	Share Based Compensation Arrangement By Share Based Payment Award Options For Exchange In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForExchangeInPeriodWeightedAverageExercisePrice	0.30
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	973750	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.20
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	29983780	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.49
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	29673	usd
	dei	Entity Central Index Key EntityCentralIndexKey	0000924515
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2023Q4	us-gaap	Accounts And Notes Receivable Net AccountsAndNotesReceivableNet	2000	usd
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	818000	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	54105000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	54105000	shares
CY2023Q4	gthp	Excessed Amount Of Insured Limitations ExcessedAmountOfInsuredLimitations	156112	usd
CY2022Q4	gthp	Agrregate Intrensic Value AgrregateIntrensicValue	0	usd
CY2023Q4	gthp	Agrregate Intrensic Value AgrregateIntrensicValue	0	usd
CY2023Q2	gthp	Agrregate Intrensic Value AgrregateIntrensicValue	0	usd
CY2024Q2	gthp	Outstanding Principal Balance Note Payable OutstandingPrincipalBalanceNotePayable	0	usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Document Period End Date DocumentPeriodEndDate	2024-06-30
	dei	Entity File Number EntityFileNumber	000-22179
	dei	Entity Registrant Name EntityRegistrantName	GUIDED THERAPEUTICS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	58-2029543
	dei	Entity Address Address Line1 EntityAddressAddressLine1	5835 Peachtree Corners East
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite B
	dei	Entity Address City Or Town EntityAddressCityOrTown	Peachtree Corners
	dei	Entity Address State Or Province EntityAddressStateOrProvince	GA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	30092
	dei	City Area Code CityAreaCode	770
	dei	Local Phone Number LocalPhoneNumber	242-8723
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	56550370	shares
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	275000	usd
CY2024Q2	us-gaap	Accounts And Notes Receivable Net AccountsAndNotesReceivableNet	2000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	632000	usd
CY2024Q2	us-gaap	Assets Assets	1251000	usd
CY2023Q4	us-gaap	Assets Assets	1669000	usd
CY2024Q2	us-gaap	Debt Default Shortterm Debt Amount DebtDefaultShorttermDebtAmount	1130000	usd
CY2023Q4	us-gaap	Debt Default Shortterm Debt Amount DebtDefaultShorttermDebtAmount	0	usd
CY2024Q2	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	12000	usd
CY2023Q4	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	0	usd
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	5732000	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	104000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	155000	usd
CY2024Q2	us-gaap	Long Term Notes Payable LongTermNotesPayable	59000	usd
CY2023Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	0	usd
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	54105000	shares
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-3806000	usd
CY2024Q2	us-gaap	Revenues Revenues	0	usd
CY2023Q2	us-gaap	Revenues Revenues	44000	usd
	us-gaap	Revenues Revenues	6000	usd
	us-gaap	Revenues Revenues	66000	usd
CY2024Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	0	usd
CY2023Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	33000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	42000	usd
CY2024Q2	us-gaap	Gross Profit GrossProfit	0	usd
CY2023Q2	us-gaap	Gross Profit GrossProfit	11000	usd
	us-gaap	Gross Profit GrossProfit	4000	usd
	us-gaap	Gross Profit GrossProfit	24000	usd
CY2024Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	222000	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	66000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	275000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	73000	usd
CY2024Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	69000	usd
CY2023Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	61000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	142000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	134000	usd
CY2024Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	364000	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1389000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	600000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2166000	usd
CY2024Q2	us-gaap	Operating Expenses OperatingExpenses	655000	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	1516000	usd
	us-gaap	Operating Expenses OperatingExpenses	1017000	usd
	us-gaap	Operating Expenses OperatingExpenses	2373000	usd
CY2024Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-655000	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1505000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1013000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2349000	usd
CY2024Q2	us-gaap	Interest Expense InterestExpense	75000	usd
CY2023Q2	us-gaap	Interest Expense InterestExpense	69000	usd
	us-gaap	Interest Expense InterestExpense	139000	usd
	us-gaap	Interest Expense InterestExpense	134000	usd
CY2024Q2	us-gaap	Interest Income Operating InterestIncomeOperating	0	usd
CY2023Q2	us-gaap	Interest Income Operating InterestIncomeOperating	0	usd
	us-gaap	Interest Income Operating InterestIncomeOperating	3000	usd
	us-gaap	Interest Income Operating InterestIncomeOperating	0	usd
CY2024Q2	gthp	Change In Fair Value Of Derivative Liability ChangeInFairValueOfDerivativeLiability	-7000	usd
CY2023Q2	gthp	Change In Fair Value Of Derivative Liability ChangeInFairValueOfDerivativeLiability	0	usd
	gthp	Change In Fair Value Of Derivative Liability ChangeInFairValueOfDerivativeLiability	-7000	usd
	gthp	Change In Fair Value Of Derivative Liability ChangeInFairValueOfDerivativeLiability	5000	usd
CY2024Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	16000	usd
CY2023Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	17000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	33000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	52000	usd
CY2024Q2	us-gaap	Other Income OtherIncome	12000	usd
CY2023Q2	us-gaap	Other Income OtherIncome	0	usd
	us-gaap	Other Income OtherIncome	12000	usd
	us-gaap	Other Income OtherIncome	0	usd
CY2024Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-54000	usd
CY2023Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-52000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-98000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-77000	usd
CY2024Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-709000	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1557000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1111000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2426000	usd
CY2024Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-709000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-1557000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1111000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2426000	usd
CY2024Q2	gthp	Deemed Dividend For Warrant Exchanges DeemedDividendForWarrantExchanges	0	usd
CY2023Q2	gthp	Deemed Dividend For Warrant Exchanges DeemedDividendForWarrantExchanges	0	usd
	gthp	Deemed Dividend For Warrant Exchanges DeemedDividendForWarrantExchanges	0	usd
	gthp	Deemed Dividend For Warrant Exchanges DeemedDividendForWarrantExchanges	-65000	usd
CY2024Q2	us-gaap	Dividends Preferred Stock DividendsPreferredStock	49000	usd
CY2023Q2	us-gaap	Dividends Preferred Stock DividendsPreferredStock	47000	usd
	us-gaap	Dividends Preferred Stock DividendsPreferredStock	88000	usd
	us-gaap	Dividends Preferred Stock DividendsPreferredStock	82000	usd
CY2024Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-758000	usd
CY2023Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1604000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1199000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2573000	usd
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.03
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.02
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.05
CY2024Q2	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	55986000	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	50970000	shares
	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	55368000	shares
	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	50138000	shares
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	55986000	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	50970000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	55368000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	50138000	shares
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-4012000	usd
CY2024Q2	gthp	Issuance Of Common Stock For Payment Of Series D Preferred Dividends Amount IssuanceOfCommonStockForPaymentOfSeriesDPreferredDividendsAmount	6000	usd
CY2024Q2	gthp	Issuance Of Common Stock For Payment Of Series F2 Preferred Dividends Amount IssuanceOfCommonStockForPaymentOfSeriesF2PreferredDividendsAmount	7000	usd
CY2024Q2	gthp	Issuance Of Common Stock For Payment Of Interest Amount IssuanceOfCommonStockForPaymentOfInterestAmount	48000	usd
CY2024Q2	gthp	Issuance Of Warrants With Debt Amount IssuanceOfWarrantsWithDebtAmount	12000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	30000	usd
CY2024Q2	gthp	Accrued Preferred Dividends Amount AccruedPreferredDividendsAmount	-49000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-709000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-4667000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-2855000	usd
CY2023Q2	gthp	Common Stock Warrants Exercised Amount CommonStockWarrantsExercisedAmount	9000	usd
CY2023Q2	gthp	Issuance Of Common Stock For Payment Of Series D Preferred Dividends Amount IssuanceOfCommonStockForPaymentOfSeriesDPreferredDividendsAmount	8000	usd
CY2023Q2	gthp	Issuance Of Common Stock For Payment Of Series F2 Preferred Dividends Amount IssuanceOfCommonStockForPaymentOfSeriesF2PreferredDividendsAmount	9000	usd
CY2023Q2	gthp	Conversion Of Series F Preferred Stock To Common Stock Amount ConversionOfSeriesFPreferredStockToCommonStockAmount	0	usd
CY2023Q2	us-gaap	Share Based Compensation ShareBasedCompensation	1119000	usd
CY2023Q2	gthp	Accrued Preferred Dividends AccruedPreferredDividends	-48000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-1557000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-3315000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-3806000	usd
	gthp	Issuance Of Common Stock For Payment Of Series D Preferred Dividends Amount IssuanceOfCommonStockForPaymentOfSeriesDPreferredDividendsAmount	15000	usd
	gthp	Issuance Of Common Stock For Payment Of Series E Preferred Dividends Amount IssuanceOfCommonStockForPaymentOfSeriesEPreferredDividendsAmount	8000	usd
	gthp	Issuance Of Common Stock For Payment Of Series F Preferred Dividends Amount IssuanceOfCommonStockForPaymentOfSeriesFPreferredDividendsAmount	54000	usd
	gthp	Issuance Of Common Stock For Payment Of Series F2 Preferred Dividends Amount IssuanceOfCommonStockForPaymentOfSeriesF2PreferredDividendsAmount	27000	usd
	gthp	Issuance Of Common Stock For Payment Of Interest Amount IssuanceOfCommonStockForPaymentOfInterestAmount	105000	usd
	gthp	Settlement Of Previously Accrued Professional Fees Through Common Stock Issuance Amount SettlementOfPreviouslyAccruedProfessionalFeesThroughCommonStockIssuanceAmount	57000	usd
	gthp	Issuance Of Warrants With Debt Amount IssuanceOfWarrantsWithDebtAmount	12000	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	60000	usd
	gthp	Accrued Preferred Dividends Amount AccruedPreferredDividendsAmount	-88000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1111000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-4667000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-2883000	usd
	gthp	Common Stock Warrants Exercised Amount CommonStockWarrantsExercisedAmount	231000	usd
	gthp	Issuance Of Common Stock For Payment Of Series D Preferred Dividends Amount IssuanceOfCommonStockForPaymentOfSeriesDPreferredDividendsAmount	14000	usd
	gthp	Issuance Of Common Stock For Payment Of Series E Preferred Dividends Amount IssuanceOfCommonStockForPaymentOfSeriesEPreferredDividendsAmount	8000	usd
	gthp	Issuance Of Common Stock For Payment Of Series F Preferred Dividends Amount IssuanceOfCommonStockForPaymentOfSeriesFPreferredDividendsAmount	53000	usd
	gthp	Issuance Of Common Stock For Payment Of Series F2 Preferred Dividends Amount IssuanceOfCommonStockForPaymentOfSeriesF2PreferredDividendsAmount	29000	usd
	gthp	Conversion Of Series E Preferred Stock To Common Stock Amount ConversionOfSeriesEPreferredStockToCommonStockAmount	0	usd
	gthp	Conversion Of Series F Preferred Stock To Common Stock Amount ConversionOfSeriesFPreferredStockToCommonStockAmount	0	usd
	gthp	Conversion Of Series F2 Preferred Stock To Common Stock Amount ConversionOfSeriesF2PreferredStockToCommonStockAmount	0	usd
	gthp	Issuance Of Common Stock For Payment Of Interest Amount IssuanceOfCommonStockForPaymentOfInterestAmount	59000	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1683000	usd
	gthp	Impact Of Warrant Exchanges Amount ImpactOfWarrantExchangesAmount	0	usd
	gthp	Accrued Preferred Dividends Amount AccruedPreferredDividendsAmount	-83000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2426000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-3315000	usd
	us-gaap	Profit Loss ProfitLoss	1111000	usd
	us-gaap	Profit Loss ProfitLoss	2426000	usd
	us-gaap	Interest And Debt Expense InterestAndDebtExpense	1000	usd
	us-gaap	Interest And Debt Expense InterestAndDebtExpense	2000	usd
	us-gaap	Depreciation Depreciation	5000	usd
	us-gaap	Depreciation Depreciation	5000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	50000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	65000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	60000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1683000	usd
	us-gaap	Servicing Liability At Fair Value Other Changes In Fair Value ServicingLiabilityAtFairValueOtherChangesInFairValue	-7000	usd
	us-gaap	Servicing Liability At Fair Value Other Changes In Fair Value ServicingLiabilityAtFairValueOtherChangesInFairValue	5000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	42000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	37000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	33000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	52000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-6000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-11000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-4000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	25000	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-52000	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-46000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	323000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-173000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-44000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-38000	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	324000	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-64000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-314000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-937000	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	200000	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	17000	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	185000	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	213000	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	195000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-2000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-18000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-316000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-955000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	591000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2313000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	275000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1358000	usd
	us-gaap	Interest Paid Net InterestPaidNet	21000	usd
	us-gaap	Interest Paid Net InterestPaidNet	47000	usd
	us-gaap	Dividends Preferred Stock Stock DividendsPreferredStockStock	88000	usd
	us-gaap	Dividends Preferred Stock Stock DividendsPreferredStockStock	82000	usd
	gthp	Deemed Dividends For Warrant Exchanges DeemedDividendsForWarrantExchanges	0	usd
	gthp	Deemed Dividends For Warrant Exchanges DeemedDividendsForWarrantExchanges	65000	usd
	gthp	Warrants Issued With Debt WarrantsIssuedWithDebt	12000	usd
	gthp	Warrants Issued With Debt WarrantsIssuedWithDebt	0	usd
	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	6000	usd
	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	0	usd
	gthp	Common Stock Issued For Payment Of Interest CommonStockIssuedForPaymentOfInterest	105000	usd
	gthp	Common Stock Issued For Payment Of Interest CommonStockIssuedForPaymentOfInterest	59000	usd
	us-gaap	Stock Issued1 StockIssued1	104000	usd
	us-gaap	Stock Issued1 StockIssued1	105000	usd
	gthp	Settlement Of Previously Accrued Professional Fees Through Common Stock Issuance SettlementOfPreviouslyAccruedProfessionalFeesThroughCommonStockIssuance	57000	usd
	gthp	Settlement Of Previously Accrued Professional Fees Through Common Stock Issuance SettlementOfPreviouslyAccruedProfessionalFeesThroughCommonStockIssuance	0	usd
	gthp	Accrued Payroll Liability Exchanged For Promissory Note AccruedPayrollLiabilityExchangedForPromissoryNote	87000	usd
	gthp	Accrued Payroll Liability Exchanged For Promissory Note AccruedPayrollLiabilityExchangedForPromissoryNote	0	usd
	gthp	Conversion Of Series E Preferred Shares Into Common Stock ConversionOfSeriesEPreferredSharesIntoCommonStock	0	usd
	gthp	Conversion Of Series E Preferred Shares Into Common Stock ConversionOfSeriesEPreferredSharesIntoCommonStock	5000	usd
	gthp	Conversion Of Series F Preferred Shares Into Common Stock ConversionOfSeriesFPreferredSharesIntoCommonStock	0	usd
	gthp	Conversion Of Series F Preferred Shares Into Common Stock ConversionOfSeriesFPreferredSharesIntoCommonStock	42000	usd
	us-gaap	Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants	200000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant areas where estimates are used include the allowance for doubtful accounts, inventory valuation, valuation of share-based compensation and the valuation of the convertible note payable derivative liability. Management bases its estimates on historical experience and on various other assumptions believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from those estimates, and such differences could be material to the Company’s financial statements.</p>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	The Company maintains a cash balance in a financial institution that is insured by the Federal Deposit Insurance Corporation up to certain federal limitations. At times, the Company’s cash balance exceeds these federal limitations. The amount in excess of insured limitations was nil and $156,112 as of June 30, 2024 and December 31, 2023, respectively.
	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	2161560	shares
CY2023Q4	gthp	Share Outstanding One ShareOutstandingOne	54105101	shares
	gthp	Common Shares Issued CommonSharesIssued	2161560	shares
CY2024Q2	gthp	Share Outstanding One ShareOutstandingOne	56266661	shares
	gthp	Schedule Of Fair Value Warrants Issued Under Black Scholes Option Pricing Model Table Textblock ScheduleOfFairValueWarrantsIssuedUnderBlackScholesOptionPricingModelTableTextblock	<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Expected term (years)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.0</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Volatility</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">389.2</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Risk-free interest rate</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.4</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Dividend yield</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.0</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:92%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Expected term (years)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.9</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Volatility</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">290.6</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Risk-free interest rate</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.7</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Dividend yield</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.0</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></tbody></table>
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	3.892	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.044	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P3Y10M24D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	2.906	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.037	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000	pure
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	206306	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	54702	usd
CY2024Q2	gthp	Description Of Standstill Agreement DescriptionOfStandstillAgreement	contingent on payments from SMI totaling $770,000 on or before July 30, 2024. In addition, because SMI did not make its scheduled payment of $100,000 on or before March 31, 2024, the Company can place a 25% surcharge on the cost of goods and services already paid for by SMI. Additionally, the Standstill Extension reduced the number of RFID chips the Company committed to shipping by 240,000 and reduced the total amount due from SMI in 2024 by $247,545
CY2024Q2	gthp	Common Stock Purchase Warrants CommonStockPurchaseWarrants	100000	shares
CY2024Q2	gthp	Discount On Note Payable DiscountOnNotePayable	11998	usd
CY2024Q2	us-gaap	Notes Payable NotesPayable	83162	usd
CY2023Q4	gthp	Outstanding Principal Balance Note Payable OutstandingPrincipalBalanceNotePayable	59422	usd
CY2024Q2	gthp	Debt Discount Short Term Note Payable DebtDiscountShortTermNotePayable	12000	usd
CY2023Q4	gthp	Debt Discount Short Term Note Payable DebtDiscountShortTermNotePayable	0	usd
CY2024Q2	us-gaap	Short Term Bank Loans And Notes Payable ShortTermBankLoansAndNotesPayable	112000	usd
CY2023Q4	us-gaap	Short Term Bank Loans And Notes Payable ShortTermBankLoansAndNotesPayable	59000	usd

Files In Submission

Name	View Source	Status
0001477932-24-004869-index-headers.html	Edgar Link	pending
0001477932-24-004869-index.html	Edgar Link	pending
0001477932-24-004869.txt	Edgar Link	pending
0001477932-24-004869-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
gthp-20240630.xsd	Edgar Link	pending
gthp_10q.htm	Edgar Link	pending
gthp_ex101.htm	Edgar Link	pending
gthp_ex101img1.jpg	Edgar Link	pending
gthp_ex101img10.jpg	Edgar Link	pending
gthp_ex101img11.jpg	Edgar Link	pending
gthp_ex101img12.jpg	Edgar Link	pending
gthp_ex101img13.jpg	Edgar Link	pending
gthp_ex101img14.jpg	Edgar Link	pending
gthp_ex101img15.jpg	Edgar Link	pending
gthp_ex101img16.jpg	Edgar Link	pending
gthp_ex101img2.jpg	Edgar Link	pending
gthp_ex101img3.jpg	Edgar Link	pending
gthp_ex101img4.jpg	Edgar Link	pending
gthp_ex101img5.jpg	Edgar Link	pending
gthp_ex101img6.jpg	Edgar Link	pending
gthp_ex101img7.jpg	Edgar Link	pending
gthp_ex101img8.jpg	Edgar Link	pending
gthp_ex101img9.jpg	Edgar Link	pending
gthp_ex102.htm	Edgar Link	pending
gthp_ex102img13.jpg	Edgar Link	pending
gthp_ex102img14.jpg	Edgar Link	pending
gthp_ex102img15.jpg	Edgar Link	pending
gthp_ex102img16.jpg	Edgar Link	pending
gthp_ex102img17.jpg	Edgar Link	pending
gthp_ex102img18.jpg	Edgar Link	pending
gthp_ex102img19.jpg	Edgar Link	pending
gthp_ex102img20.jpg	Edgar Link	pending
gthp_ex102img21.jpg	Edgar Link	pending
gthp_ex102img22.jpg	Edgar Link	pending
gthp_ex102img23.jpg	Edgar Link	pending
gthp_ex102img24.jpg	Edgar Link	pending
gthp_ex103.htm	Edgar Link	pending
gthp_ex103img1.jpg	Edgar Link	pending
gthp_ex103img10.jpg	Edgar Link	pending
gthp_ex103img11.jpg	Edgar Link	pending
gthp_ex104.htm	Edgar Link	pending
gthp_ex104img2.jpg	Edgar Link	pending
gthp_ex105.htm	Edgar Link	pending
gthp_ex105img29.jpg	Edgar Link	pending
gthp-20240630_cal.xml	Edgar Link	unprocessable
gthp-20240630_def.xml	Edgar Link	unprocessable
gthp-20240630_pre.xml	Edgar Link	unprocessable
gthp_10q_htm.xml	Edgar Link	completed
gthp_ex106.htm	Edgar Link	pending
gthp_ex107.htm	Edgar Link	pending
gthp_ex108.htm	Edgar Link	pending
gthp_ex31.htm	Edgar Link	pending
gthp_ex32.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
gthp-20240630_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$GTHP
GUIDED THERAPEUTICS INC Stock $gthp

2024 Q3 Form 10-Q Financial Statement

#000147793224004869 Filed on August 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GTHP GUIDED THERAPEUTICS INC Stock $gthp

2024 Q3 Form 10-Q Financial Statement

#000147793224004869 Filed on August 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GTHP
GUIDED THERAPEUTICS INC Stock $gthp